Antares Pharma Announces Availability of OTREXUP Injection for Subcutaneous Use to Treat Rheumatoid Arthritis (RA) and Psoriasis in Adults, and Polyarticular Idiopathic Arthritis in Children

Antares Pharma

today announced the availability of OTREXUP™, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. OTREXUP was approved by the FDA in October 2013. OTREXUP is available at distribution centers throughout the USA.